Chronic Lymphocytic Leukemia Clinical Trial
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
Summary
This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of relapsing multiple sclerosis
Active disease
Greater than or equal to (≥) 2 relapses in prior 2 years or 1 relapse in the year prior to screening and/or ≥1 gadolinium (Gd) enhancing lesion
Exclusion Criteria:
Treatment with anti-cluster of differentiation 20 (CD20) monoclonal antibody within the last 12 months
Treatment with alemtuzumab within the last 12 months
Pregnant or nursing mothers
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 12 Locations for this study
Phoenix Arizona, 85018, United States
Pasadena California, 91105, United States
Torrance California, 90502, United States
Aurora Colorado, 80045, United States
Fort Collins Colorado, 80528, United States
Lexington Kentucky, 40509, United States
Teaneck New Jersey, 07666, United States
Akron Ohio, 44320, United States
Columbus Ohio, 43201, United States
Knoxville Tennessee, 37922, United States
Round Rock Texas, 78681, United States
San Antonio Texas, 78258, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.